Systems, products, compounds, and methods can be applied and/or used by a person to facilitate and promote the production of nitric oxide to be used by a person for health benefits. The systems, products, and devices include a nitric oxide bath system. The systems and methods can comprise one or more compounds that when mixed are adapted to produce nitric oxide gas, with at least one nitrite compound and at least one acid compound. The nitric oxide gas may then be delivered to a user transdermally via one or more bath applications.

The subject matter of the invention is a therapeutic device in the form of a cylindrical chamber which comprises a hyperbaric chamber, LED matrices (5) and inductive coil rings (10, 11, 12, 13), constructed in one inseparable set in the form of a chamber of 200-280 cm in length and diameter of the round cylinder (70-130 cm).

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

A method for enhancing tissue oxygenation by bathing the body or part of a body in water infused with oxygenated microbubbles.

A system for delivering oxygen to a substantially stationary patient without coupling a device to the body of the patient is disclosed. The system includes a source of oxygen coupled to a delivery system wherein the delivery system has a pump configured to pressurize oxygen and an elongate hollow member operatively coupled to the pump. The elongate hollow member has a proximal end and a distal end and is constructed to receive oxygen in its proximal end and deliver oxygen to the patient out the distal end. The length and diameter of the elongate member, the flow of oxygen through the elongate member, and the distance from the distal end of the elongate member to the face of the patient are optimized to collimate a stream of oxygen such that when the stream of oxygen reaches the patients face it envelops the face of the patient.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and/or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

A energizing bed, primarily comprising an enclosed space of the bed with a power control box and a door for entering and exiting. A heating apparatus is connected to the base board of the bed while an anion generator and oxygen generator are attached to the outside of the bed body. One of the bed ends has air holes for supplying anions and oxygen as well as being the side to mount the power control box, which will control the heating apparatus, anion generator, and oxygen generator. This allows the person to be treated to lie down on the bed and revitalize oneself by allowing cell metabolism to happen in its ideal environment.

A therapeutic device for treating one or more conditions associated with a user's nasal cavities, sinuses, and/or ear canals includes a housing having an opening, an acoustic vibrator within the housing that is operable to provide an acoustic vibration to the user, a fan within the housing that is operable to provide a pressure to the user and a power supply that provides power to the acoustic vibrator and the fan. A mask is connected to the housing at the opening and includes a nasal interface appliable around the nose of the user, a nasal chamber in which the user's nostrils are located and an aperture through which the fan delivers the pressure.

The invention relates to a treatment apparatus comprising an envelope that can be placed on or around a body part of a person such that the envelope has a positioning area (Z) for said body part of the person, the envelope being provided with an inlet (8) for a gaseous medium and an outlet for discharging the gaseous medium present in the envelope. According to the invention, the apparatus comprises a control system (11) for controlling the flow of the gaseous medium in order to direct the gaseous medium entering the envelope via the inlet (8) outside the positioning area (Z), and to homogenise the gaseous medium present in the envelope.

A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.